& Events
& Events
News
& Events
Oct 17, 2019 Inversago Pharma Strengthens its Board of Directors with the Appointment of Two Industry Experts
MONTREAL (CANADA) – 17 October 2019 – Today Inversago Pharma Inc., a preclinical-stage biotech company developing novel CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of two seasoned pharma executives in line with the Company’s aim to attract first-class industry leaders for their guidance and expertise.
Sep 25, 2019 Inversago Pharma Strengthens its Clinical Leadership Team
MONTREAL (CANADA) – 25 September 2019 – Today Inversago Pharma Inc., a preclinical-stage biotech company developing new CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of Dr. Caroline Fradette as Vice-President, Clinical Research.
Sep 19, 2019 2019 PWS Research Symposium, Oct. 3-4 – Inversago Presentation Details
Safety Assessment in Non-Human Primates of New Cannabinoid-1 Receptor Blockers to Treat Hyperphagia, Obesity and Related Metabolic Disorders in PWS. The 2019 PWS Research Symposium is organized by the Foundation for Prader-Willi Research.
Aug 22, 2019 Inversago Pharma to present at 2019 PWS Research Symposium, to be held on October 3-4 in New Orleans, LA.
MONTREAL (CANADA) AUGUST 22, 2019 – Inversago Pharma today announces that François Ravenelle, Founder and CEO, has been invited to share the company’s most recent results in a presentation entitled: